Paper Details

  1. Home
  2. Paper Details

Vasopressin: a new target for the treatment of heart failure.

Author: AdamsKirkwood F, GattisWendy, GheorghiadeMihai, LeeCraig R, O'connorChristopher M, PattersonJ Herbert, WatkinsMichael L

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Vasopressin antagonists, such as tolvaptan and conivaptan, show promising results in treating heart failure by increasing free water excretion, reducing body weight, improving congestion symptoms, and moderately increasing serum sodium concentrations.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Arginine vasopressin is a peptide hormone that modulates a number of processes implicated in the pathogenesis of heart failure. Numerous vasopressin antagonists are currently under development for the treatment of this syndrome. METHODS: Preclinical and clinical data describing the effe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/12851603

データ提供：米国国立医学図書館（NLM）

Vasopressin: A New Oasis in the Desert of Heart Failure

Heart failure, like a vast desert, can be a daunting challenge. This research explored the role of vasopressin, a peptide hormone, in the pathogenesis of heart failure. The authors reviewed preclinical and clinical data on vasopressin and its antagonists, delving into the complex landscape of this disease.

Vasopressin Antagonists: A Potential Source of Relief

The study found that vasopressin, through its interaction with V(1a) and V(2) receptors, plays a crucial role in regulating several physiological processes, including body fluid regulation, vascular tone, and cardiovascular contractility. However, in heart failure, vasopressin levels are chronically elevated, potentially exacerbating the condition. This is akin to a desert that experiences excessive rainfall, leading to flooding and further complications. The research suggests that vasopressin antagonists, such as tolvaptan and conivaptan, might offer a potential solution, like building a dam to control the flow of water.

The Future of Vasopressin Antagonists in Heart Failure Treatment

While early findings are promising, further research is needed to fully understand the role of vasopressin antagonism in heart failure treatment. This is like carefully exploring a new oasis, ensuring that the water is safe and that the resources are sufficient to sustain life. The researchers acknowledge that phase III clinical trials are necessary to solidify the potential of vasopressin antagonists as a viable treatment option for heart failure.

Dr.Camel's Conclusion

This research, like a caravan exploring a new route across the desert, sheds light on the potential role of vasopressin antagonists in managing heart failure. While more research is needed, the findings offer a glimmer of hope for those struggling with this challenging condition. It's a reminder that even in the vast expanse of the desert of heart failure, new oases of hope can be discovered.
Date :
  1. Date Completed 2003-07-25
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

12851603

DOI: Digital Object Identifier

S0002870302947083

Related Literature

Article Analysis
・Effects of tolvaptan (low blood sodium)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.